NEW YORK, July 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Analogic Corporation (NASDAQ: ALOG), Masimo Corporation (NASDAQ: MASI), Dr. Reddy's Laboratories Limited (NYSE: RDY), BioSpecifics Technologies Corp. (NASDAQ: BSTC) and Bio-Rad Laboratories, Inc. (NYSE: BIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4358-100free.
--
Analogic Corporation Analyst Notes
On June 20, 2014, Analogic Corporation (Analogic) announced that its Director, Kevin Melia, passed away on June 17, 2014 after a brief illness. According to the Company, Mr. Melia joined Analogic's Board of Directors in April 2009 and served as a member of the audit and compensation committees. Jim Green, President and CEO, Analogic said, "Kevin's contribution to our Board has been immeasurable. Since joining our Board in 2009, he has provided invaluable guidance to me and our senior management team. He was a good and valued friend. Our thoughts and prayers go out to his family, and we will miss him." The full analyst notes on Analogic are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/ALOG/report.pdf
--
Masimo Corporation Analyst Notes
On June 25, 2014, Masimo Corporation (Masimo) announced CE Mark of the new TFA-1 transflectance forehead adhesive sensor that provides clinicians the power of Masimo SET® Measure-through Motion and Low Perfusion™ Pulse Oximetry on an alternative monitoring site for rapid detection of oxygen saturation changes during low perfusion. According to the Company, the TFA-1 single-use sensors for adult and pediatric patients utilizes Masimo SET® and provide SpO2, pulse rate, perfusion index, and PVI® measurements. Masimo added that Masimo SET® reduces false alarms, accurately detects true alarms, and provides measurements when other pulse oximeters fail. The Company added that the accuracy of Masimo SET® pulse oximetry in real-world conditions has been clinically proven to improve patient outcomes and reduce cost of care by providing accurate and reliable SpO2 measurements. The full analyst notes on Masimo are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/MASI/report.pdf
--
Dr. Reddy's Laboratories Limited Analyst Notes
On June 27, 2014, Dr. Reddy's Laboratories Limited (Dr. Reddy's) announced the launch of Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg, and 60 mg, which is a therapeutic equivalent generic version of CYMBALTA® (Duloxetine Delayed-Release Capsules), in the U.S. market on June 26, 2014. Dr. Reddy's stated that its Abbreviated New Drug Application (ANDA) has been approved by the U.S. Food & Drug Administration. The full analyst notes on Dr. Reddy's are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/RDY/report.pdf
--
BioSpecifics Technologies Corp. Analyst Notes
On June 27, 2014, BioSpecifics Technologies Corp. (BioSpecifics) announced that it will be added to the Russell 3000® and Russell Global Indexes, effective at the close of the U.S. markets on the date of announcement, as part of Russell Investments' annual reconstitution of its U.S. and global equity indexes. The Company stated that Russell indexes are widely used by investment managers as well as institutional investors for index funds and also as benchmarks for both passive and active investment strategies. BioSpecifics added that the annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May and ranks them by total market capitalization. Thomas L. Wegman, President of BioSpecifics said, "We are focused on building shareholder value and expect that our inclusion in the Russell Indexes will generate liquidity in our stock through more visibility in the investment community, and by attracting index funds." The full analyst notes on BioSpecifics are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/BSTC/report.pdf
--
Bio-Rad Laboratories, Inc. Analyst Notes
On June 23, 2014, Bio-Rad Laboratories, Inc. (Bio-Rad) announced the launch of the BioPlex® 2200 25-OH Vitamin D kit that offers a fully-automated method for the quantitative measurement of the total 25-hydroxyvitamin D in human serum, for use outside the U.S. on the Company's BioPlex® 2200 system. The Company stated that a number of recent studies has shown associations of Vitamin D deficiency with increased risk of cardiovascular disease, autoimmune disease, and cancer, and added that physicians have started including Vitamin D testing as part of the routine assessment of a patient's overall health. John Goetz, Executive Vice President and President of Clinical Diagnostics Group said, "We are pleased to offer the BioPlex 2200 25-OH Vitamin D kit to address this important area of testing. The Vitamin D kit expands our already extensive menu of autoimmune and infectious disease assays and offers our customers another option to streamline their testing." The full analyst notes on Bio-Rad are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/BIO/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
